Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis
Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
180 participants
May 22, 2025
INTERVENTIONAL
Conditions
Summary
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment
45 patients are infused with equal volume of control solution and receive regulatory treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06882811